IPG's Battery-Led Growth and Medical Pivot Mask a 40% Selloff

Revenue up 11% and book-to-bill above 1 for a third straight quarter, but the stock is in freefall — the market is pricing in execution risk on a strategic transformation.

IPGP · Earnings Call · 2026-08-04

IPG Photonics (IPGP) turned in another strong quarter on August 4, 2026, with revenue up 11% year over year to $279 million and adjusted EPS of $0.58 above the high end of guidance. The more important story is the battery manufacturing and stationary storage momentum: “growth was led by strength in Industrial Solutions, primarily in welding applications as we continue to benefit from increased demand and business wins for our solutions in battery manufacturing” — Mark M. Gitin, Chief Executive Officer and Director · 2026-08-04. Management points to an unexpected coexistence of EV growth and an AI-driven data center buildout that is silently becoming the next growth engine for industrial lasers.

Batteries and the Data Center Energy Demand Boom

Across the earnings call, CEO Mark Gitin repeatedly highlighted the unusual pull from grid-adjacent applications. In the Q&A he explained: “stationary storage... is being driven by data centers for AI and also, you know, some grid stability for solar and other renewables” — Mark M. Gitin, Chief Executive Officer and Director · 2026-08-04. That nuance matters, because it means IPGP is no longer a pure play on EV adoption shocks; instead it is riding an AI-fueled infrastructure cycle. The company's own Industrial Solutions segment grew 16% year over year, and management said emerging growth products now account for 58% of total revenue, up from 53% last quarter. This mix shift toward higher-growth applications—fueled by the company's AMB lasers and proprietary beam delivery—helps justify the bold guidance of continued double-digit growth.

What’s becoming a bigger piece of this now is actually stationary storage, which is being driven by data centers for AI and also, you know, some grid stability for solar and other renewables.
Mark M. Gitin, Chief Executive Officer and Director · 2026-08-04

The near-term financials confirm the narrative: total revenue has now grown for three consecutive quarters year-over-year on a double-digit basis, a sharp contrast to the 2024-2025 downturn. Book-to-bill has been above 1.0 for the third straight quarter, giving management confidence in shippable backlog. But those who expected faster sequential momentum will notice that Q3 revenue guidance ($265-295 million) is roughly flat versus Q2's $279 million — perhaps one reason the stock is down almost 40% over the last 90 days despite the strong operational report.

Medical Scale Strategy and the Lumibird Acquisition

The headline event was the binding offer to acquire Lumibird Medical, a leader in ophthalmic laser systems. On the call, Mark Gitin stated: “This acquisition will allow us to... accelerates IPG’s strategic evolution by meaningfully expanding our advanced solutions revenue into attractive, higher-margin medical markets” — Mark M. Gitin, Chief Executive Officer and Director · 2026-08-04. That rationale aligns with the company's declared ambition to reach hundreds of millions in advanced-solutions revenue. Lumibird adds roughly $1 billion to IPGP's addressable medical market, creating a scaled platform in urology, ophthalmology, and surgical lasers.

This acquisition marks a distinct pivot in IPGP's capital allocation — after years of heavy investment in industrial fiber lasers, the company is now deliberately channeling its enormous net cash pile (> $1.2 billion) into higher-margin, durable-demand end markets. Management expects the deal (closing in Q4 2026) to be accretive to gross margin, EBITDA, and adjusted EPS in its first year, which is consistent with prior commentary on margin expansion and a greater mix of medical devices.

The Margin Recovery and the Shadow of Tariffs

Financially, IPGP is still healing from the trough. Gross margin, which collapsed to 23% in Q3 2024, has clawed back to 40.4%. CFO Tim Mammen was candid: “We benefited from German R&D tax credit... lower inventory provisions... and improved product costs.” But tariffs remain a persistent drag. The company recognized ~$4.7 million in tariff refunds in Q2, adding 170 bps of gross margin benefit, while Q3 guidance still assumes a 150 bps tariff headwind. The Gross Margin now sits at 40.4% versus a peak of 57% in 2018, and even after several quarters of momentum, it remains about 800 basis points below its 2022 level.

Defense momentum also moved forward: Crossbow shipments to Lockheed Martin began in Q2, and tests at White Sands Missile Range validated the system in harsh environments — “multiple Crossbow systems under test at the same time, really showcasing that some cooperative engagement tactics with the units” (Mark Gitin). While defense revenue is still modest, the foundation for scalable directed energy sales is being set.

Why This Matters

IPGP's earnings are no longer just about cyclical recovery; the company is transforming its mix — from simple laser boxes to high-spec subsystems for battery lines, from commodity cutting tools to a full-fledged medical platform, and from drone defense prototypes to an AI-adjacent energy infrastructure play. The Industrial Solutions success in battery welding gives it exposure to the same data center demand that powers semiconductor and AI names.

Investors appear to be discounting near-term execution risk: the stock has fallen 38.6% in the past 90 days, in sharp contrast to improving financials. That move may reflect concern about flat Q3 guidance and potential dilutive effects of the acquisition, but with net cash still $1.2B and no debt, IPGP has the balance sheet to fund both organic investment and value-enhancing M&A. The market appears to be waiting for evidence that the growth rate can be sustained at a faster pace, but IPGP's own trajectory — new products, a higher-margin medical arm, and a firing directed-energy system — clearly points to a company in motion.